Orforglipron
LY3502970
Quick Answer
Orforglipron is not a peptide. Searchers land here because they conflate "oral GLP-1" with peptide content. The page needs to name the molecular class first, then explain why orforglipron competes with peptide injectables on access and adherence.
Mechanism
Non-peptide oral small-molecule agonist of the GLP-1 receptor. Targets the same receptor as semaglutide but via a distinct, non-peptide chemistry that survives the gut without an absorption enhancer and does not require the fasting/water protocol used for oral semaglutide.
Half-Life
Approximately 29-49 hours (supports once-daily oral dosing)
Administration
Technical Protocol
Orforglipron: Non-Peptide Oral GLP-1 Research Profile
Overview
Orforglipron (LY3502970) is a small-molecule, non-peptide, oral GLP-1 receptor agonist being developed by Eli Lilly. It is the first credible non-peptide challenger to injectable GLP-1 peptides at obesity-relevant efficacy.
It is included in this peptide reference for one reason: searches for "oral GLP-1" and "GLP-1 pill" routinely map to peptide pages expecting an answer. The honest answer is that orforglipron is not a peptide.
How It Differs from Oral Semaglutide
- Oral semaglutide: still the peptide semaglutide, delivered with an absorption enhancer (SNAC), requiring a fasting/water protocol before dosing.
- Orforglipron: a small molecule with no absorption enhancer, no fasting window, flexible daily dosing.
Same receptor, completely different chemistry and manufacturing profile.
Research Evidence
Phase 3 readouts reported placebo-adjusted weight reductions in the low-double-digit percent range in obesity populations, and meaningful A1C reductions in T2D populations. Efficacy approached — though did not clearly exceed — injected semaglutide in the studied contexts, and remained below top-dose tirzepatide.
Why It Matters
- Adherence: daily oral pill removes needle aversion as a barrier.
- Supply: small molecules scale differently than peptide injectables, which could ease the supply pressure that defined the 2023-2025 GLP-1 shortage era.
- Access: manufacturing economics of small-molecule pills are fundamentally different.
Safety Framing
Typical GLP-1 class themes apply — GI tolerability driving titration design, the usual pancreatitis and gallbladder monitoring. Nothing unique to the oral form beyond the absence of injection-site reactions.
This information is for research and educational purposes only. Orforglipron is investigational and not approved for human use.
Frequently Asked Questions
Is orforglipron a peptide?
No. Orforglipron is a non-peptide small molecule. It targets the same GLP-1 receptor as semaglutide, but the chemistry is entirely different, which is why it can be dosed as a daily pill without an absorption enhancer.
Is orforglipron as effective as semaglutide?
Public Phase 3 readouts placed weight-loss and A1C effects broadly in the range of injected semaglutide in studied populations, without clearly exceeding top-tier injectables like high-dose tirzepatide.
How should Orforglipron be stored?
Room-temperature oral dosage form; follow labeling for storage specifics
Continue the Research Path
Orforglipron (Foundayo): First Non-Peptide Oral GLP-1, FDA Approved 2026
Orforglipron (brand name Foundayo) was FDA-approved April 1, 2026 — the first oral, non-peptide GLP-1 receptor agonist for weight loss. This guide explains what it is, how it differs from oral semaglutide, and what ATTAIN trial data showed.
Oral vs Injectable GLP-1: Access, Adherence, and Efficacy Tradeoffs
Side-by-side comparison of oral and injectable GLP-1 options in 2026: oral semaglutide, oral wegovy, orforglipron, and weekly injectable peptides. What actually differs beyond the needle.
Semaglutide: Mechanism, Evidence, Side Effects
Evidence-first guide to semaglutide covering mechanism, clinical outcomes, tolerability, and status context.
GLP-1 Agonists: Semaglutide, Tirzepatide & Metabolic Regulation
Scientific overview of GLP-1 and dual-agonist metabolic peptides, mechanism, outcomes, and limitations.
Answer-First Research Snapshot
Evidence
The strongest opportunity is to explicitly distinguish non-peptide small molecules from peptide GLP-1 agonists (both injected and oral), and to frame Phase 3 results accurately against injected semaglutide and tirzepatide.
Dosage Context
Dose questions reflect interest in oral dosing simplicity relative to oral semaglutide (which requires a fasting-and-water protocol). Keep framing research-oriented.
Status
Late-stage investigational; not an approved therapy. The page should be framed as high-interest, evidence-maturing, and molecular-class-clarifying.
Lead with "not a peptide" — same receptor target, different chemistry.
Distinguish from oral semaglutide (peptide + SNAC absorption enhancer).
Explain why supply and access economics differ for a small molecule vs injectable peptide.
Related Metabolic Peptides
Tirzepatide
A novel dual agonist for GLP-1 and GIP receptors, used for weight management and diabetes.
metabolicSemaglutide
A widely used GLP-1 analog for type 2 diabetes and chronic weight management.
metabolicMOTS-c
A mitochondria-derived micropeptide studied for its metabolic and anti-aging effects.
metabolicAOD-9604
A GH fragment specifically designed for fat reduction and cartilage repair.